Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Apple Inc (AAPL) vs Revvity Inc (RVTY) Price & Performance

Revvity IncTrade

Price performance (Past 24H)

Key statistics

Apple Inc vs Revvity Inc — how do they compare? Apple Inc trades at $301.94 (market cap $4.45T), while Revvity Inc trades at $115.88 (market cap $12.91B). The key difference: Apple Inc is far larger — about 344.7× Revvity Inc's market cap, and Apple Inc pays the higher dividend (0.35%). Which is the better fit depends on your goals.

AAPLRVTY
Market Cap
$4.45T$12.91B
Volume
100,358,844
Sector
TechnologyTechnology
52-Week High
$340.08$117.75
52-Week Low
$224.90$82.26
Enterprise Value
$4.47T$15.23B
Dividend Yield
0.35%0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Apple Inc

AAPL trades at $301.14, down 2.31% on the day, with a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate. Revenue grew to $416.16B in 2025, and net income margin improved to 26.91%. However, valuation ratios like P/E of 34.97 and P/B of 41.39 appear elevated. Recent news highlights AI potential through its device ecosystem but also store closures and union disputes.

The outlook is mixed: solid fundamentals and analyst buy consensus support upside to the $337.63 price target, but high valuations and technical bearishness near-term pose risks. Key opportunities include AI integration and cash flow strength; risks involve competitive pressures, regulatory scrutiny, and execution on growth initiatives.

Revvity Inc

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Apple Inc

Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.

Read more on AAPL

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY